NASDAQ:AMGN Amgen (AMGN) Stock Price, News & Analysis $317.48 -2.25 (-0.70%) (As of 10/3/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Amgen Stock (NASDAQ:AMGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$315.46▼$319.7350-Day Range$312.50▼$337.3852-Week Range$249.70▼$346.85Volume1.52 million shsAverage Volume2.50 million shsMarket Capitalization$170.31 billionP/E Ratio45.35Dividend Yield2.83%Price Target$325.55Consensus RatingModerate Buy Company OverviewAmgen Inc. is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. Established in 1980 by William Bowes from Cetus Corporation and Winston Salser from UCLA, Amgen is now one of the world's largest independent biotechnology companies, with over 24,000 employees worldwide. The company's primary focus is on molecular biology and biochemistry, intending to provide healthcare solutions based on recombinant DNA technology.Neulasta, one of Amgen's most prominent selling product lines, is used to prevent infections in patients undergoing cancer chemotherapy. Enbrel is another famous selling product line for Amgen, used in the treatment of rheumatoid arthritis and other autoimmune diseases. The company's other products have various applications in treating cancer, anemia, osteoporosis and other conditions.Amgen has a rich history of strong leadership, with the appointment of several successful CEOs since its inception. Robert A. Bradway is the current CEO and was brought to Amgen in May 2012 following his predecessor's retirement. Bradway has led the company to new heights with strategic acquisitions and partnerships.Amgen has made at least five major corporate acquisitions. In 2019, the company announced it would acquire Nuevolution AB and the Otezla drug program from Celgene and a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. These acquisitions have strengthened Amgen's drug pipeline and provided new revenue streams for the company. In March 2021, Amgen announced its plans to acquire Five Prime Therapeutics and its lead research drug candidate, bemarituzumab, for $1.9 billion. It also agreed to acquire Rodeo Therapeutics for up to $720 million. These acquisitions are part of the company's ongoing efforts to expand its drug pipeline and bring new treatments to patients.In 2012, Amgen faced legal issues when it pleaded guilty and agreed to pay $150 million in criminal penalties and $612 million in damages to resolve 11 related whistleblower complaints. Amgen has also faced criticism for lobbying for a two-year extension on sales of drugs, including Sensipar, without government controls, which will cost taxpayers an estimated $500 million. However, the company remains committed to providing innovative and effective healthcare solutions for patients.Amgen's success can be attributed to its commitment to innovation, strategic acquisitions, strong partnerships and top-end leadership. The company's impressive portfolio of products and its commitment to the community has solidified Amgen's position as a leader in biopharmaceuticals.Written by Jeffrey Neal JohnsonRead More… The massive trade idea that’s being censored (Ad)There is a red-hot sector right now that it seems like Google doesn’t want us to talk about… Because when we talk about it in email, sometimes those messages have trouble making it through to you. And it’s not just email! Videos from Youtube are also being removed. We don’t know exactly why it’s happening… Or if it’s being done manually or by an algorithm…. But we do know that you probably are going to want to see what they’re censoring.Decide for yourself when you get the full details here. Amgen Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks88th Percentile Overall ScoreAMGN MarketRank™: Amgen scored higher than 88% of companies evaluated by MarketBeat, and ranked 157th out of 995 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingAmgen has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 11 buy ratings, 11 hold ratings, and 1 sell rating.Amount of Analyst CoverageAmgen has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amgen's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth5.28% Earnings GrowthEarnings for Amgen are expected to grow by 5.28% in the coming year, from $19.49 to $20.52 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amgen is 45.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 134.07.Price to Earnings Ratio vs. SectorThe P/E ratio of Amgen is 45.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 140.60.Price to Earnings Growth RatioAmgen has a PEG Ratio of 2.98. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmgen has a P/B Ratio of 27.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amgen's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.68% of the float of Amgen has been sold short.Short Interest Ratio / Days to CoverAmgen has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Amgen has recently increased by 6.13%, indicating that investor sentiment is decreasing significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldAmgen pays a meaningful dividend of 2.82%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAmgen has been increasing its dividend for 13 years.Dividend CoverageThe dividend payout ratio of Amgen is 128.57%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Amgen will have a dividend payout ratio of 43.86% next year. This indicates that Amgen will be able to sustain or increase its dividend.Read more about Amgen's dividend. Sustainability and ESG3.9 / 5Environmental Score-2.42 Percentage of Shares Shorted1.68% of the float of Amgen has been sold short.Short Interest Ratio / Days to CoverAmgen has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Amgen has recently increased by 6.13%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.62 News SentimentAmgen has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 34 news articles for Amgen this week, compared to 21 articles on an average week.Search Interest37 people have searched for AMGN on MarketBeat in the last 30 days. This is an increase of 3% compared to the previous 30 days.MarketBeat FollowsOnly 18 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is a decrease of -10% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Amgen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.69% of the stock of Amgen is held by insiders.Percentage Held by Institutions76.50% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amgen's insider trading history. AMGN Stock News HeadlinesHow I’d Invest $100K Today to Get Filthy RichHow would I invest a chunk of money today? Say $10K or even $100K? I’d load up on dividend magnet stocks, sit back and watch Fed Chair Jay Powell pumpOctober 2 at 10:16 PM | marketbeat.comAmgen (AMGN) Rose Owing To The Announcement Of Promising Data For Its Novel MedicationOctober 3 at 11:31 AM | msn.comSeven “Forever Stocks” could enrich shareholders for decades A few weeks ago, I asked my research team to investigate the top 10 best-performing stocks of the last 30 years. And the results will shock you!October 3, 2024 | InvestorPlace (Ad)Amgen (NASDAQ:AMGN) Has A Somewhat Strained Balance SheetOctober 3 at 9:55 AM | finance.yahoo.comFederal Judge Rules Amgen Must Face Tax Liability Lawsuit That Alleges Reckless Concealment Of $10.7B Tax BillOctober 3 at 6:30 AM | benzinga.comLA LA ANTHONY PARTNERS WITH AMGEN TO SHARE CANDID, BEHIND-THE-SCENES LOOK AT HOW PLAQUE PSORIASIS AFFECTS HER LIFEOctober 1 at 9:00 AM | prnewswire.comShort Interest in Amgen Inc. (NASDAQ:AMGN) Rises By 6.1%October 1 at 7:35 AM | americanbankingnews.comAmgen Inc. to Post FY2024 Earnings of $19.48 Per Share, Cantor Fitzgerald Forecasts (NASDAQ:AMGN)October 1 at 1:12 AM | americanbankingnews.comSee More Headlines AMGN Stock Analysis - Frequently Asked Questions How have AMGN shares performed this year? Amgen's stock was trading at $288.02 on January 1st, 2024. Since then, AMGN shares have increased by 10.2% and is now trading at $317.48. View the best growth stocks for 2024 here. How were Amgen's earnings last quarter? Amgen Inc. (NASDAQ:AMGN) issued its quarterly earnings data on Tuesday, August, 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.01 by $0.04. The company's revenue for the quarter was up 20.1% on a year-over-year basis. Read the conference call transcript. Does Amgen have any subsidiaries? Amgen subsidiaries include these companies: TeneoBio, Five Prime Therapeutics, Rodeo Therapeutics, Otezla, Nuevolution, Catherex, Catherex, and others. Who are Amgen's major shareholders? Top institutional investors of Amgen include AMF Tjanstepension AB (0.02%), Czech National Bank (0.02%), JLB & Associates Inc. (0.01%) and Jacobs & Co. CA (0.01%). Insiders that own company stock include Amgen Inc, Murdo Gordon, Jonathan P Graham, Robert Eckert, Nancy A Grygiel, Nancy A Grygiel and R Sanders Williams. View institutional ownership trends. How do I buy shares of Amgen? Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Amgen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV) and Walt Disney (DIS). Company Calendar Last Earnings8/06/2024Dividend Payable8/06/2024Ex-Dividend for 8/6 Dividend8/16/2024Today10/03/2024Next Earnings (Confirmed)10/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:AMGN CUSIP03116210 CIK318154 Webwww.amgen.com Phone(805) 447-1000Fax805-447-1010Employees26,700Year Founded1980Price Target and Rating Average Stock Price Target$325.55 High Stock Price Target$405.00 Low Stock Price Target$215.00 Potential Upside/Downside+2.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage24 Analysts Profitability EPS (Most Recent Fiscal Year)$7.00 Trailing P/E Ratio45.35 Forward P/E Ratio16.29 P/E Growth2.98Net Income$6.72 billion Net Margins10.12% Pretax Margin11.40% Return on Equity161.72% Return on Assets10.81% Debt Debt-to-Equity Ratio9.64 Current Ratio1.26 Quick Ratio0.89 Sales & Book Value Annual Sales$30.93 billion Price / Sales5.51 Cash Flow$24.94 per share Price / Cash Flow12.73 Book Value$11.65 per share Price / Book27.25Miscellaneous Outstanding Shares536,435,000Free Float532,734,000Market Cap$170.31 billion OptionableOptionable Beta0.61 Social Links This page (NASDAQ:AMGN) was last updated on 10/3/2024 by MarketBeat.com Staff From Our PartnersThe world’s smartest man is in their crosshairsElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredMassive NVIDIA Sell-Off: Are We Headed for a Market Collapse?You may have heard about NVIDIA's CEO dumping shares of his own company. He sold 4.4 million shares this ye...Behind the Markets | SponsoredHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | SponsoredWho are Nvidia’s New Silent Partners?Nvidia knows it can’t stand still as AI continues to grow at an exponential rate. That’s why CEO Jensen Hua...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Amgen Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Amgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.